<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05089877</url>
  </required_header>
  <id_info>
    <org_study_id>CP-2021-02</org_study_id>
    <nct_id>NCT05089877</nct_id>
  </id_info>
  <brief_title>FREEZE-AFIB Post-Market Study</brief_title>
  <official_title>Outcomes of Surgical AF Ablation Using cryoICE Cryoablation System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AtriCure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AtriCure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is proposed herein is to gather clinical data on the safety and performance of the&#xD;
      CRYOF device.&#xD;
&#xD;
      Specifically, data from this study will be used for submission to regulatory authorities in&#xD;
      Europe, China and other geographies as needed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from Death, Stroke (regardless of level of disability), myocardial infarction, and major bleeding events.</measure>
    <time_frame>30 days post procedure</time_frame>
    <description>Death, stroke (regardless of level of disability), myocardial infarction, and major bleeding events within 30-days of the index ablation procedure. Measured by number of patients with Treatment-Related Adverse Events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from any documented AF, AFL or AT lasting &gt;30 seconds in the duration of the last follow-up visit off antiarrhythmic therapy (except of AADs at doses not exceeding those previously failed</measure>
    <time_frame>12-24 months post procedure</time_frame>
    <description>Freedom from any documented atrial fibrillation (AF), atrial flutter (AFL), or atrial tachycardia (AT) lasting &gt;30 seconds in duration at the last follow-up visit off antiarrhythmic therapy (except of AADs at doses not exceeding those previously failed). Measured by 24-hour Holter Monitoring.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from any documented AF, AFL, or AT lasting &gt;30 seconds at the last follow-up visit regardless of Class I or III AADs</measure>
    <time_frame>12-24 months post procedure</time_frame>
    <description>Freedom from any documented AF, AFL, or AT lasting &gt;30 seconds at the last follow-up visit regardless of Class I or III AADs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from any documented AF, AFL, or AT lasting &gt;30 seconds at the last follow-up visit in the absence of Class I or III AADs.</measure>
    <time_frame>12-24 months post procedure</time_frame>
    <description>Freedom from any documented AF, AFL, or AT lasting &gt;30 seconds at the last follow-up visit in the absence of Class I or III AADs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute procedural success defined as documentation of sinus rhythm at the end of the procedure.</measure>
    <time_frame>At end of procedure</time_frame>
    <description>Acute procedural success defined as documentation of sinus rhythm at the end of the procedure.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Freedom from pacemaker implant or overall device or Surgical Ablation procedures Related to Adverse Events</measure>
    <time_frame>12-24 months post procedure</time_frame>
    <description>Freedom from pacemaker implant or overall device or Surgical Ablation procedures Related to Adverse Events</description>
  </other_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surgical Ablation</intervention_name>
    <description>The AtriCure cryoICE® cryoFORMTM cryoablation probe is used in the cryosurgical treatment of cardiac arrhythmias by freezing target tissues, creating an inflammatory response (cryonecrosis) that blocks the electrical conduction pathway.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have undergone concomitant surgical AF ablation using the CRYOF device under&#xD;
        investigation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is greater than or equal to 18 years of age.&#xD;
&#xD;
          2. Subject has documented history of atrial fibrillation.&#xD;
&#xD;
          3. Subjects who received surgical ablation for their atrial fibrillation using CRYOF and&#xD;
             on whom at least the following lesions were performed: Left and right pulmonary vein&#xD;
             isolation, roof and floor lines, mitral annulus line and a connecting lesion from left&#xD;
             atrial appendage to left pulmonary vein coronary sinus lesion and LAA exclusion , with&#xD;
             a lesion duration of at least 2 minutes.&#xD;
&#xD;
          4. Stable subject that underwent non-emergent cardiac surgical procedure(s) on&#xD;
             cardiopulmonary bypass including open-heart surgery for one or more of the following:&#xD;
             mitral valve repair or replacement, aortic valve repair or replacement, tricuspid&#xD;
             valve repair or replacement, or coronary artery bypass procedures, or atrial septal&#xD;
             defect (ASD) repair&#xD;
&#xD;
          5. Left Ventricular Ejection Fraction ≥ 30% (determined by echocardiography or cardiac&#xD;
             catheterization performed within 90 days of enrollment as documented in patient&#xD;
             medical history).&#xD;
&#xD;
          6. Subject is willing and able to provide written informed consent.&#xD;
&#xD;
          7. Subject is willing and able to return for scheduled follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Stand-alone AF without indication(s) for concomitant CABG and/or valve surgery.&#xD;
&#xD;
          2. Previous left sided ablation procedures procedure.&#xD;
&#xD;
          3. Untreated atrial flutter and symptomatic ventricular arrythmia&#xD;
&#xD;
          4. Known carotid artery stenosis greater than 80% prior to index ablation procedure.&#xD;
&#xD;
          5. Prior history of ischemic stroke or hemorrhagic stroke&#xD;
&#xD;
          6. History of MI with ST elevation within 6 weeks prior to the index ablation&#xD;
&#xD;
          7. Documented AF duration of greater than 10 years.&#xD;
&#xD;
          8. Large left atrial size i.e., LA diameter &gt;7 cm prior to the index ablation procedure.&#xD;
&#xD;
          9. Subjects with active systemic infection prior to index ablation procedure.&#xD;
&#xD;
         10. Subjects who had documented severe peripheral arterial occlusive disease defined as&#xD;
             claudication with minimal exertion prior to the ablation procedure.&#xD;
&#xD;
         11. Subjects with history of renal failure requiring dialysis or hepatic failure prior to&#xD;
             the ablation procedure.&#xD;
&#xD;
         12. A known drug and/or alcohol addiction.&#xD;
&#xD;
         13. Mental impairment or other conditions which may not allow the subject to understand&#xD;
             the nature, significance, and scope of the study.&#xD;
&#xD;
         14. Subjects who are pregnant&#xD;
&#xD;
         15. Subjects who had preoperative need for mechanical circulatory support or intravenous&#xD;
             inotropes.&#xD;
&#xD;
         16. Subjects who are on anti-arrhythmic drug therapy for the treatment of another&#xD;
             arrhythmia.&#xD;
&#xD;
         17. Subjects in currently undergoing chemotherapy.&#xD;
&#xD;
         18. Subjects on long term treatment with oral or injected steroids (not including&#xD;
             intermittent use of inhaled steroids for respiratory diseases).&#xD;
&#xD;
         19. Subjects who had known connective tissue disorders at the time of index ablation&#xD;
             procedure&#xD;
&#xD;
         20. Subjects who had known hypertrophic obstructive cardiomyopathy at the time of index&#xD;
             ablation procedure&#xD;
&#xD;
         21. Subjects with known cold agglutinin.&#xD;
&#xD;
         22. Subjects who had or tested positive for COVID-19&#xD;
&#xD;
         23. Subjects with bleeding disorders and/or inability to receive anticoagulation&#xD;
&#xD;
         24. Subjects undergoing aortic dissection surgery as index procedure.&#xD;
&#xD;
         25. Cardiac surgical re-intervention since the index cardiac surgery with concomitant AF&#xD;
             ablation procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Erik J Fransen, MSc, PhD</last_name>
    <phone>+31622707172</phone>
    <email>efransen@atricure.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nfii Ndikintum, PhD</last_name>
    <phone>(513) 644-8192</phone>
    <email>NNdikintum@atricure.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surgical ablation</keyword>
  <keyword>Cryo probe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

